Session I

• PHA-022121: Efficacy in a monkey bradykinin challenge model translated to human Anne Lesage Switzerland
• Investigation of neutrophil granulocyte function in patients with Hereditary Angioedema Erika Kajdácsi Hungary
• Detection of C1-inhibitor/C1-inhibitor antibody complexes and its connection with underlying diseases of acquired angioedema Zsófia Pólai Hungary
• Activation of MASP-3 by PCSK6 links the complement and the proprotein convertase systems in the blood József Dobó Hungary
• Intravascular Bradykinin formation is modulated by the combined presence of pk, HK, C1INH, and PRCP Alvin Schmaier United States

Session II

• Preclinical studies of BMN 331 in mice and non-human primates demonstrate continuous, clinically meaningful production of C1-INH and phenotypic correction, warranting evaluation of this AAV-mediated gene therapy for treatment of Hereditary Angioedema in humans Jill Woloszynek United States
• NTLA-2002: CRISPR-Mediated Gene Knockout of KLKB1 as a potential single-dose treatment for Hereditary Angioedema (HAE) James Butler United States
• The constellation of SERPING1 variants associated with C1-INH-HAE Christian Drouet France
• Understanding disease mechanisms of Hereditary Angioedema through rna seq transcriptome profiling Jonathan A Bernstein United States

Session III

• Heart-rate variability evaluation during attacks in patients with Hereditary Angioedema due to C1-Inhibitor deficiency Francesca Perego Italy
• Pregnancy outcome in patients with Hereditary Angioedema: A single center experience from North India Ankur Jindal India
• Prodromes predict oncoming HAE attacks: results of a prospective study Iris Leibovich-Nassi Israel
• New concepts in the classification of angioedema syndromes Avner Reshef Israel

Poster session I

• HAE Junior: A patient organization with a holistic approach Camelia Isaic Czech Republic
• Lanadelumab efficacy is sustainable over time: Findings from the HELP and HELP OLE studies Emel Aygören-Pürsün Germany
• Reimbursement of the C1-Inhibitor esterase laboratory testing facilitates the early diagnosis of Hereditary Angioedema Noémi-Anna Bara Romania
• Efficacy of subcutaneous C1-inhibitor long-term prophylaxis in C1-INH-HAE Ana Entrala Spain
• Predicting clinical benefits of bradykinin B2 receptor ligands using the human umbilical vein contractility assay François Marceau Canada
• Searching for genetic biomarkers for Hereditary Angioedema due to C1-inhibitor deficiency (C1-INH-HAE) Anastasios E. Germenis Greece
• Laryngeal attack in Hereditary Angioedema in the emergency room: a case report Benítez Lima, Ana Karen Mexico
• Detailed long term follow-up of a patient with acquired angioedema due to C1-inhibitor deficiency Zsófia Pólai Hungary
• A spectrum of Serping1 mutations and clinical characterisation of Czech Hereditary Angioedema patients Hana Grombirikova Czech Republic
• Clinical and genetic diversity of Hereditary Angioedema in Latvia Adine Kanepa Latvia

Virtual Budapest sightseeing

Session IV

• Recombinant human C1 esterase inhibitor as prophylaxis for idiopathic non-histaminergic angioedema Mehran Alizadeh Aghdam The Netherlands
• Diagnosis of Hereditary Angioedema in Latin America is improving, however specific lab tests and therapies for many countries are not available Anete Sevciovic Grumach Brazil
• Long-term safety and efficacy of Berotralstat in Hereditary Angioedema (HAE): special considerations in patients transitioning from androgens Marcin Stobiecki Poland
• Garadacimab, a novel monoclonal antibody targeting activated factor XII (FXIIa), prevents attacks in patients with Hereditary Angioedema (HAE) Markus Magerl Germany
• Fast improvement of Hereditary Angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phas Andrea Zanichelli United Kingdom

Session V

• ‘C1 inhibitor normal’ versus ‘C1 inhibitor deficient’ Hereditary Angioedema: A false dichotomy? Samantha Chan Australia
• Covid19 in HAE patients – case series from a single centre John Dempster United Kingdom
• Bariatric surgery in patients with Hereditary Angioedema due to C1-inhibitor deficiency David Loli-Ausejo Spain
• Hereditary Angioedema: a case report Natalja Kurjane Latvia
• Acquired Angioedema secondary to prostate cancer treated with lanadelumab Babak Aberumand Canada

Session VI

• Angioedema Quality of Life Questionnaire (AE-QoL) - How to interpret its scores Karsten Weller Germany
• Lifestyle medicine for Hereditary Angioedema Erik van den Top New Zealand
• Psychiatric and clinical characteristics of Hereditary Angioedema patients who experienced attacks during COVID-19 Nihal Gökmen Turkey
• Use of subcutaneous human C1 esterase inhibitor concentrate as long -term prophylaxis therapy in patients with Hereditary Angioedema with C1 inhibitor deficiency during the COVID19 pandemic period Krasimira Baynova Spain
• Latin-American Hae individuals with abnormal C1 Inhibitor infected by SARS Cov2 showed mild clinical manifestations Ricardo Dario Zwiener Colombia
• Quality of life on some Colombian Hae Patients Jairo Rodriguez Colombia

Poster session II

• Impact of Lanadelumab in Hereditary Angioedema: A case series of 12 patients in Canada Aled Iaboni Canada
• Living with HAE in Australia – Initial findings from a national observational study Constance Katelaris Australia
• Angioedema and low C4 as initial manifestations leading to the diagnosis that is even rarer than HAE Sladjana Andrejevic Serbia
• Novel genetic modifiers of the clinical phenotype in patients with Hereditary Angioedema due to C1 inhibitor deficiency Nina Rupar Slovenia
• Overview of SERPING1 variations identified in Hungarian patients with Hereditary Angioedema Dorottya Csuka Hungary
• SERPING1 gene promoter variation in Turkish patient with HAE Aycan Aşik Turkey
• Real-world effectiveness and disease/treatment management associated with lanadelumab long-term prophylaxis in HAE: design for a retrospective chart review Markus Magerl Germany
• Burden of illness and treatment patterns in patients with Hereditary Angioedema type I and II: A retrospective observational chart review Henriette Farkas Hungary
• HAE treatment – Single or multiple pathways to the rescue? Anna Valerieva Bulgaria
• Can HAE patients with C1INH deficiency be completely alleviated from disease symptoms? Yes, we can! Hilary Longhurst New Zealand
• Successful prophylactic recombinant human C1-esterase inhibitor for the treatment of Idiopathic non-histaminergic angioedema (iNHAE): a case report Mehran Alizadeh Aghdam The Netherlands

Virtual Banquet

Session VII

• A national audit of Hereditary and Acquired Angioedema in New Zealand 2015-2019 Ke Li Chow New Zealand
• Characterization of Hereditary Angioedema due to mutations in the F12 gene in seven Spanish families Francisca Vílchez-Sánchez Spain
• Clinical and therapeutic characteristics of adult patients with idiopathic angioedema Mehran Alizadeh Aghdam The Netherlands
• The characteristics and the incidence of upper airway edema in patients with Hereditary and acquired angioedema with C1 inhibitor deficiency Zsuzsanna Balla Hungary
• Diagnosing pediatric patients with Hereditary C1-inhibitor deficiency – experience from the Hungarian Angioedema Center of reference and excellence Noémi Andrási Hungary
• Clinical and demographic characteristics of patients with Hereditary Angioedema in Canada Erika Lee Canada
• This is HAE International Anthony Castaldo, Henrik Balle Boysen United States